Targeted Oncology's Coverage of the ASCO Annual Meeting | Conferences

Coverage of the 2020 American Society of Clinical Oncology Virtual Scientific Program, held May 29-31, 2020.

Belzutifan Shows Strong Responses in RCC and Other VHL-Associated Lesions

June 09, 2021

Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.

Second-Line Cetuximab Use in the Real-World Setting Correlate With Longer Time on Treatment and Other Outcomes

June 09, 2021

Second-line treatment with cetuximab in patients with metastatic colorectal cancer given after irinotecan or oxaliplatin-based regimen failure, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

Abiraterone Added to ADT and Docetaxel Prolongs PFS in De Novo mCSPC

June 09, 2021

In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.